Safety and tolerability of a one-time, in-office administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: The Reducing Adenoviral Patient Infected Days (RAPID) study

Ellen Shorter, Meredith Whiteside, Jennifer Harthan, Mathew S. Margolis, Andrew T. Hartwick, Spencer Johnson, Mary Migneco, Christina Morettin, Christian K. Olson, Julia Huecker, Tammy Than, Mae O. Gordon

Research output: Contribution to journalArticle

Abstract

Purpose: To report safety and tolerability of a one-time administration of ophthalmic 5% povidone-iodine (5% PVP-I) in a double-masked randomized trial for the treatment of adenoviral conjunctivitis (Ad-Cs). Methods: Of 212 participants screened, 56 eligible participants with red eye symptoms ≤4 days and a positive adenoviral rapid immunoassay were randomized to a one-time administration of ophthalmic 5% PVP-I or preservative free artificial tears (AT). Safety was assessed by corneal fluorescein staining (baseline, immediate post-administration and Day 1) and visual acuity (VA) (baseline and Day 1). Tolerability was assessed using participant-rated overall ocular discomfort (baseline, immediately post-administration and on Day 1. Results: In the 5% PVP-I group, corneal staining increased immediately post-administration but returned to baseline levels by Day 1. There was no change in VA between baseline and Day 1 in either 5% PVP-I or AT groups (p = 0.87). In the 5% PVP-I group, there was no change in participant-rated overall discomfort immediately post-administration (p = 0.78) or on day 1 (p = 0.10) compared to baseline. In the AT group, participant-rated overall discomfort was lower immediately post-administration but returned to baseline levels by Day 1. One adverse event was reported in the 5% PVP-I group on Day 1–2 that was classified as not related to treatment. Conclusion: These results suggest ophthalmic 5% PVP-I used as a one-time treatment is safe and well tolerated by patients with Ad-Cs.

Original languageEnglish
Pages (from-to)828-832
Number of pages5
JournalOcular Surface
Volume17
Issue number4
DOIs
StatePublished - Oct 2019

Keywords

  • Adenoviral conjunctivitis
  • Betadine
  • Corneal staining
  • Povidone-iodine
  • Safety

Fingerprint Dive into the research topics of 'Safety and tolerability of a one-time, in-office administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: The Reducing Adenoviral Patient Infected Days (RAPID) study'. Together they form a unique fingerprint.

  • Cite this